Amicus Therapeutics (NASDAQ:FOLD) Given New $17.00 Price Target at JPMorgan Chase & Co.

Amicus Therapeutics (NASDAQ:FOLD) had its price target upped by JPMorgan Chase & Co. from $16.00 to $17.00 in a research note released on Tuesday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.

Several other research analysts have also commented on FOLD. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Guggenheim increased their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Jefferies Financial Group initiated coverage on Amicus Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $18.00 price target for the company. Morgan Stanley decreased their price target on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Finally, Bank of America raised their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $17.63.

Amicus Therapeutics Trading Down 1.9 %

NASDAQ:FOLD opened at $10.49 on Tuesday. The stock’s 50 day moving average price is $11.09 and its 200 day moving average price is $10.61. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. Amicus Therapeutics has a 52 week low of $9.02 and a 52 week high of $14.57.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,901 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total transaction of $98,762.50. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $11,083,175. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $11.46, for a total transaction of $85,950.00. Following the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $10,161,054.84. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bradley L. Campbell sold 7,901 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $11,083,175. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,401 shares of company stock valued at $352,038 in the last 90 days. 2.20% of the stock is currently owned by insiders.

Institutional Trading of Amicus Therapeutics

Institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. bought a new position in Amicus Therapeutics in the second quarter worth $8,386,000. M&G Plc lifted its holdings in shares of Amicus Therapeutics by 12.4% during the 2nd quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after acquiring an additional 82,728 shares during the period. Edgestream Partners L.P. boosted its position in shares of Amicus Therapeutics by 1,290.4% during the 1st quarter. Edgestream Partners L.P. now owns 270,164 shares of the biopharmaceutical company’s stock valued at $3,183,000 after acquiring an additional 250,734 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its stake in Amicus Therapeutics by 7.8% in the first quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock valued at $1,183,000 after acquiring an additional 7,304 shares during the period. Finally, Fiera Capital Corp raised its position in Amicus Therapeutics by 1.1% in the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock worth $52,382,000 after purchasing an additional 58,113 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.